Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simbrinza as Adjunctive Therapy to Travatan in Normal Tension Glaucoma
NCT03150160Phase 4Completed
- Sponsor
- Novartis
- Start
- Sep 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in normal tension glaucoma (NTG) comparing Simbrinza + Travatan with Placebo + Travatan (2 arms). Primary endpoint: Mean Change From Baseline in Diurnal Intraocular Pressure at Week 6. Started Sep 2017; status: completed.
02
Drugs
brinzolamide + brimonidine
03
Conditions
normal tension glaucoma (NTG)
Beyond the preview
Go deeper on NCT03150160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150160.